After Kenya, Ethiopia and Vietnam are the next in line for the access programme, and Novartis hopes to eventually extend it to at least 30 countries. To help guide the roll-out, Novartis is ...

and Vietnam. Since 2020, the global SMA treatment landscape has progressed, with three treatments now approved, according to Novartis. Along with Zolgensma – which made its debut in 2019 ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much broader prostate cancer population. The new approval, which triples ...

Novartis is paying Kyorin $55 million upfront for exclusive global rights to develop, manufacture and commercialize KRP-M223, a preclinical mast-cell-targeting candidate for chronic spontaneous ...

TOKYO -- Swiss pharmaceutical company Novartis has pegged its cancer-targeting radiopharmaceutical business as its next growth pillar, looking to make it "at least a $10 billion business" over the ...

Porter, Michael E., Mark R. Kramer, and David Lane. "Social Business at Novartis: Arogya Parivar." Harvard Business School Case 715-411, December 2014. (Revised ...